A phase 2 study of immunogenic cell death inducer PT-112 in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Bryce, Alan Haruo
Karp, Daniel D.
Tagawa, Scott T.
Nordquist, Luke T.
Rathkopf, Dana E.
Adra, Nabil
Dorff, Tanya B.
Baeck, Johan
O'Donnell, Joseph Francis
Ames, Tyler David
Yim, Christina Y.
Price, Matthew
Scher, Howard I.
机构：
[1] Mayo Clin, Phoenix, AZ USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Cornell Univ, Weill Cornell Med Coll, New York, NY USA
[4] Urol Canc Ctr PC, Omaha, NE USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Weill Cornell Med, New York, NY USA
[7] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Promontory Therapeut Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS292
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.
    Glaser, Zachary A.
    Avulova, Svetlana
    Stocks, Blair
    Penson, David F.
    Moses, Kelvin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [42] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A drug-drug interaction study on the combination of cabazitaxel with enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Belderbos, Bodine P. S.
    Bins, Sander
    van Leeuwen, Roelof W. F.
    De Hoop, Esther Omen
    van der Meer, Nelly
    de Bruijn, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [44] Phase II cohort study in patients with metastatic castration-resistant prostate cancer (mCRPC) with new cohorts
    Rexer, Heidrun
    Retz, Margitta
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (06) : 504 - 505
  • [45] Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
    Lin, Jianqing
    Elkon, Jacob
    Ricart, Brittany
    Palmer, Erica
    Zevallos-Delgado, Christian
    Noonepalle, Satish
    Burgess, Brooke
    Siegel, Robert
    Ma, Yan
    Villagra, Alejandro
    ONCOLOGIST, 2021, 26 (12): : E2136 - E2142
  • [46] Final results of a phase II study of cyclophosphamide, etoposide, and estramustine in patients with castration-resistant prostate cancer.
    Zhang, W.
    Shams, M.
    Moffett, P.
    Rabinowits, G.
    Salvador, C.
    Kloecker, G. H.
    Laber, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shore, Neal
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph
    Costin, Dan
    Adra, Nabil
    Cullberg, Marie
    Teruel, Carlos Fernandez
    Morris, Thomas
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 278 - 285
  • [48] Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
    Petrylak, Daniel P.
    Loriot, Yohann
    Shaffer, David R.
    Braiteh, Fadi
    Powderly, John
    Harshman, Lauren C.
    Conkling, Paul
    Delord, Jean-Pierre
    Gordon, Michael
    Kim, Joseph W.
    Sarkar, Indrani
    Yuen, Kobe
    Kadel, Edward E.
    Mariathasan, Sanjeev
    O'Hear, Carol
    Narayanan, Sujata
    Fasso, Marcella
    Carroll, Susheela
    Powles, Thomas
    CLINICAL CANCER RESEARCH, 2021, 27 (12) : 3360 - 3369
  • [49] SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
    Stangl, Andrew
    Willner, Christopher
    Maahs, Lucas
    Burmeister, Charlotte
    Hwang, Clara
    Pilling, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [50] Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.
    Von Amsberg, Gunhild
    Zilles, Mirjam
    Gild, Philipp
    Alsdorf, Winfried
    Boeckelmann, Lukas
    Langebrake, Claudia
    Oh-Hohenhorst, Su Jung
    Tilki, Derya
    Graefen, Markus
    Dyshlovoy, Sergey
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345